228 related articles for article (PubMed ID: 22290982)
1. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Collins VL; Marchaim D; Pogue JM; Moshos J; Bheemreddy S; Sunkara B; Shallal A; Chugh N; Eiseler S; Bhargava P; Blunden C; Lephart PR; Memon BI; Hayakawa K; Abreu-Lanfranco O; Chopra T; Munoz-Price LS; Carmeli Y; Kaye KS
Antimicrob Agents Chemother; 2012 Apr; 56(4):2173-7. PubMed ID: 22290982
[TBL] [Abstract][Full Text] [Related]
2. Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
Johnson JK; Robinson GL; Pineles LL; Ajao AO; Zhao L; Albrecht JS; Harris AD; Thom KA; Furuno JP
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167543
[TBL] [Abstract][Full Text] [Related]
3. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
4. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
[TBL] [Abstract][Full Text] [Related]
5. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
6. Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia.
Lye DC; Wijaya L; Chan J; Teng CP; Leo YS
Ann Acad Med Singap; 2008 Oct; 37(10):831-4. PubMed ID: 19037516
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria.
Fong JJ; Rosé L; Radigan EA
Ann Pharmacother; 2012 Mar; 46(3):347-52. PubMed ID: 22395250
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
11. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
12. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
Gutiérrez-Gutiérrez B; Bonomo RA; Carmeli Y; Paterson DL; Almirante B; Martínez-Martínez L; Oliver A; Calbo E; Peña C; Akova M; Pitout J; Origüen J; Pintado V; García-Vázquez E; Gasch O; Hamprecht A; Prim N; Tumbarello M; Bou G; Viale P; Tacconelli E; Almela M; Pérez F; Giamarellou H; Cisneros JM; Schwaber MJ; Venditti M; Lowman W; Bermejo J; Hsueh PR; Mora-Rillo M; Gracia-Ahulfinger I; Pascual A; Rodríguez-Baño J;
J Antimicrob Chemother; 2016 Jun; 71(6):1672-80. PubMed ID: 26907184
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
Kiremitci A; Dinleyici EC; Erben N; Durmaz G; Yargic ZA; Aybey AD; Usluer G
Expert Opin Pharmacother; 2008 Jun; 9(9):1441-9. PubMed ID: 18518776
[TBL] [Abstract][Full Text] [Related]
14. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.
Mody RM; Erwin DP; Summers AM; Carrero HA; Selby EB; Ewell AJ; Moran KA
Ann Clin Microbiol Antimicrob; 2007 Jun; 6():6. PubMed ID: 17553151
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Hu Z; Chu Y; Chen S; Cao B; Su J; Gui B; Duan Q; Zhang S; Shao H; Kong H; Badal RE; Xu Y
Antimicrob Agents Chemother; 2016 Jan; 60(1):245-51. PubMed ID: 26482308
[TBL] [Abstract][Full Text] [Related]
16. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.
Frakking FN; Rottier WC; Dorigo-Zetsma JW; van Hattem JM; van Hees BC; Kluytmans JA; Lutgens SP; Prins JM; Thijsen SF; Verbon A; Vlaminckx BJ; Cohen Stuart JW; Leverstein-van Hall MA; Bonten MJ
Antimicrob Agents Chemother; 2013 Jul; 57(7):3092-9. PubMed ID: 23612198
[TBL] [Abstract][Full Text] [Related]
17. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
Canoui E; Tankovic J; Bige N; Alves M; Offenstadt G
Med Mal Infect; 2014 May; 44(5):235-7. PubMed ID: 24780641
[No Abstract] [Full Text] [Related]
18. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010).
Cantón R; Loza E; Aznar J; Calvo J; Cercenado E; Cisterna R; Romo FG; Hontangas JL; Calvo CR; Barrenechea AI; Tubau F; Weber I; Yuste P; Cavanillas R;
Rev Esp Quimioter; 2011 Dec; 24(4):223-32. PubMed ID: 22173194
[TBL] [Abstract][Full Text] [Related]
19. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
20. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
